Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer

Author：                

Publisher： Spandidos Publications

E-ISSN： 1791-3004|12|4|5771-5779

ISSN： 1791-2997

Source： Molecular Medicine Reports, Vol.12, Iss.4, 2015-01, pp. : 5771-5779

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatinbased adjuvant chemotherapy

By                

Oncology Letters, Vol. 5, Iss. 3, 2013-01 ,pp. : 935-942

Spandidos Publications

Access to resources Recommend Favorite

Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy

By Huang Zhao-Hui   Hua Dong   Du Xiang  

Cancer Chemotherapy and Pharmacology, Vol. 64, Iss. 5, 2009-10 ,pp. : 1001-1007

Springer Publishing Company

Access to resources Recommend Favorite

Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1

By Aoyama Toru  

Gastric Cancer, Vol. 14, Iss. 2, 2011-06 ,pp. : 150-154

Springer Publishing Company

Access to resources Recommend Favorite

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer

By  

Oncology Letters, Vol. 9, Iss. 3, 2015-01 ,pp. : 1451-1457

Spandidos Publications

Access to resources Recommend Favorite

Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy

By Shi Yan  

Tumor Biology, Vol. 32, Iss. 2, 2011-04 ,pp. : 381-390

Springer Publishing Company

Access to resources Recommend Favorite